Group 1 - Green Leaf Pharmaceutical (02186) announced a share transfer agreement involving Nanjing Green Leaf, a subsidiary, where an investor will transfer 25% of its stake for RMB 1.086 billion to Nanjing Xinshi [1] - Nanjing Xinshi, a limited partnership, will acquire the stake, while Shandong Green Leaf, a wholly-owned subsidiary, subscribed to approximately 33.2% of Nanjing Xinshi's partnership interests for RMB 200 million [1] - The remaining interests in Nanjing Xinshi are held by China Cinda with about 66.4% and by Hangzhou Xinshi and Yantai Hexin as general partners, each holding approximately 0.2% [1] Group 2 - Following the share transfer, Nanjing Xinshi is expected to secure bank financing of up to RMB 648 million, with guarantees provided by Yantai Green Leaf and Shenzhen Green Leaf [2] - The purpose of the transaction is to introduce third-party investors to provide financing and support for the payment of the share transfer, ensuring timely access to necessary funds for acquiring the 25% stake in Nanjing Green Leaf [2] - Nanjing Green Leaf and its subsidiaries primarily engage in the production and sale of pharmaceuticals, focusing on cancer treatment [2]
绿叶制药(02186)：南京信石拟10.86亿元收购南京绿叶25%股权